Today, Bausch + Lomb announced the US availability of a new redness-targeting eye drop option: Lumify (brimonidine tartrate ophthalmic solution 0.025%). According to the company, these over-the-counter drops are the first to use low-dose brimonidine to treat eye redness. “In clinical trials, Lumify eye drops demonstrated a strong safety and efficacy profile with low risk for rebound redness and 95% symptom improvement seen at one minute and lasting up to eight hours,” the company said in a press release.
Additionally, Lumify differs from other commercially available redness relievers because it is an alpha-2-adrenergic receptor (AR) agonist rather than an alpha-1 or mixed alpha-1/alpha-2 AR agonist. This could improve eye oxygen and help reduce the risk for redness and tachyphylaxis, the company says.
Learn more at www.LumifyEyeDrops.com/professional.